Þögli faraldurinn – sýklalyfjaónæmi

dc.contributor.author	Kristinsson, Karl Gústaf
dc.date.accessioned	2022-11-24T01:04:22Z
dc.date.available	2022-11-24T01:04:22Z
dc.date.issued	2022-03-03
dc.identifier.citation	Kristinsson , K G 2022 , ' Þögli faraldurinn – sýklalyfjaónæmi ' , Læknablaðið , bind. 108 , nr. 3 , bls. 119 . https://doi.org/10.17992/lbl.2022.03.678
dc.identifier.issn	1670-4959
dc.identifier.other	62659323
dc.identifier.other	4461731e-9985-40bd-8a7a-59d401349cbc
dc.identifier.other	35230255
dc.identifier.other	85125552693
dc.identifier.other	unpaywall: 10.17992/lbl.2022.03.678
dc.identifier.uri	https://hdl.handle.net/20.500.11815/3659
dc.format.extent	1
dc.format.extent	682679
dc.format.extent	119
dc.language.iso	is
dc.relation.ispartofseries	Læknablaðið; 108(3)
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Sýklafræði
dc.subject	Sýklalyfjaónæmi
dc.subject	Anti-Bacterial Agents/adverse effects
dc.subject	COVID-19
dc.subject	Drug Resistance, Bacterial
dc.subject	Humans
dc.subject	Pandemics
dc.subject	SARS-CoV-2
dc.subject	Drug Resistance, Microbial
dc.subject	Almenn læknisfræði
dc.title	Þögli faraldurinn – sýklalyfjaónæmi
dc.title.alternative	The silent pandemic - antimicrobial resistance
dc.type	/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/editorial
dc.identifier.doi	10.17992/lbl.2022.03.678
dc.relation.url	http://www.scopus.com/inward/record.url?scp=85125552693&partnerID=8YFLogxK
dc.contributor.department	Læknadeild
dc.contributor.department	Önnur svið
dc.contributor.department	Rannsóknaþjónusta